JP5576402B2 - ヒドロキサム酸誘導体 - Google Patents

ヒドロキサム酸誘導体 Download PDF

Info

Publication number
JP5576402B2
JP5576402B2 JP2011547997A JP2011547997A JP5576402B2 JP 5576402 B2 JP5576402 B2 JP 5576402B2 JP 2011547997 A JP2011547997 A JP 2011547997A JP 2011547997 A JP2011547997 A JP 2011547997A JP 5576402 B2 JP5576402 B2 JP 5576402B2
Authority
JP
Japan
Prior art keywords
group
cancer
mmol
compound
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011547997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515776A5 (enExample
JP2012515776A (ja
Inventor
ユー チェン
イー チェン
Original Assignee
ユーロ−セルティーク エス．エイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーロ−セルティーク エス．エイ． filed Critical ユーロ−セルティーク エス．エイ．
Publication of JP2012515776A publication Critical patent/JP2012515776A/ja
Publication of JP2012515776A5 publication Critical patent/JP2012515776A5/ja
Application granted granted Critical
Publication of JP5576402B2 publication Critical patent/JP5576402B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0013—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2011547997A 2009-01-23 2010-01-07 ヒドロキサム酸誘導体 Active JP5576402B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US14700209P 2009-01-23 2009-01-23
US61/147,002 2009-01-23
US15649609P 2009-02-28 2009-02-28
US61/156,496 2009-02-28
US25215609P 2009-10-15 2009-10-15
US61/252,156 2009-10-15
US25265209P 2009-10-17 2009-10-17
US61/252,652 2009-10-17
PCT/US2010/020373 WO2010085377A2 (en) 2009-01-23 2010-01-07 Hydroxamic acid derivatives

Publications (3)

Publication Number Publication Date
JP2012515776A JP2012515776A (ja) 2012-07-12
JP2012515776A5 JP2012515776A5 (enExample) 2013-02-21
JP5576402B2 true JP5576402B2 (ja) 2014-08-20

Family

ID=42356377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011547997A Active JP5576402B2 (ja) 2009-01-23 2010-01-07 ヒドロキサム酸誘導体

Country Status (17)

Country Link
US (3) USRE46144E1 (enExample)
EP (1) EP2389375B1 (enExample)
JP (1) JP5576402B2 (enExample)
CN (1) CN102186842B (enExample)
CA (1) CA2750413C (enExample)
CY (1) CY1116602T1 (enExample)
DK (1) DK2389375T3 (enExample)
ES (1) ES2544803T3 (enExample)
HR (1) HRP20150778T1 (enExample)
HU (1) HUE025349T2 (enExample)
ME (1) ME02254B (enExample)
PL (1) PL2389375T3 (enExample)
PT (1) PT2389375E (enExample)
RS (1) RS54192B1 (enExample)
SI (1) SI2389375T1 (enExample)
SM (1) SMT201500196B (enExample)
WO (1) WO2010085377A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5749017B2 (ja) 2008-01-22 2015-07-15 ダウ アグロサイエンシィズ エルエルシー ５−フルオロピリミジン誘導体
USRE46144E1 (en) * 2009-01-23 2016-09-13 Purdue Pharmaceutical Products L.P. Hydroxamic acid derivatives
JP5784603B2 (ja) 2009-08-07 2015-09-24 ダウ アグロサイエンシィズ エルエルシー Ｎ１−スルホニル−５−フルオロピリミジノン誘導体
UA107671C2 (en) * 2009-08-07 2015-02-10 Dow Agrosciences Llc N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
UA106889C2 (uk) 2009-08-07 2014-10-27 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Похідні n1-ацил-5-фторпіримідинону
UA112284C2 (uk) 2009-08-07 2016-08-25 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Похідні 5-фторпіримідинону
WO2011085084A1 (en) 2010-01-07 2011-07-14 Dow Agrosciences Llc THIAZOLO[5,4-d] PYRIMIDINES AND THEIR USE AS AGROCHEMICALS
CN101928234B (zh) * 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
WO2011113175A1 (zh) * 2010-03-15 2011-09-22 Gao Feng 阿糖胞苷前药衍生物及其在抗癌抗肿瘤中的用途
WO2012096832A2 (en) * 2011-01-12 2012-07-19 Crystal Biopharmaceutical Llc Hdac inhibiting derivatives of camptothecin
US8658660B2 (en) 2011-08-17 2014-02-25 Dow Agrosciences, Llc. 5-fluoro-4-imino-3,4-dihydropyrimidin-2-(1H)-ones derivatives
CN102993102B (zh) * 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
PL2758052T3 (pl) 2011-09-18 2018-10-31 Euro-Celtique S.A. Kompozycja farmaceutyczna zawierająca inhibitor HDAC i cyklopolisacharyd
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
TWI573792B (zh) * 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
CN102584737A (zh) * 2012-02-07 2012-07-18 盛世泰科生物医药技术(苏州)有限公司 抑制组蛋白去乙酰酶的物质的组成和使用
EP2725029A1 (en) * 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof
RU2015131149A (ru) 2012-12-28 2017-02-03 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи N-(замещенные)-5-фтор-4-имино-3-метил-2-оксо-3,4-дигидропиримидин-1(2н)-карбоксамидные производные
EP2938194B1 (en) 2012-12-28 2019-11-27 Adama Makhteshim Ltd. N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2h)-carboxylate derivatives
UA117123C2 (uk) 2012-12-28 2018-06-25 Адама Махтешім Лтд. Похідні 1-(заміщений бензоїл)-5-фтор-4-іміно-3-метил-3,4-дигідропіримідин-2(1h)-ону
CN112094262A (zh) 2012-12-31 2020-12-18 阿达玛马克西姆股份有限公司 作为杀真菌剂的化合物
CN103340845B (zh) * 2013-06-26 2015-03-18 浙江省食品药品检验研究院 药物组合物
WO2015081867A1 (zh) * 2013-12-04 2015-06-11 杭州民生药物研究院有限公司 吉西他滨衍生物、含该衍生物的组合物及所述衍生物的制药用途
CN106028816A (zh) 2013-12-31 2016-10-12 阿达玛马克西姆股份有限公司 用防治谷类中真菌的协同杀真菌混合物
NZ722438A (en) 2013-12-31 2018-01-26 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one and processes for their preparation
US10241232B2 (en) 2014-02-03 2019-03-26 Halliburton Energy Services, Inc. Geomechanical and geophysical computational model for oil and gas stimulation and production
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
KR20170077131A (ko) * 2014-10-28 2017-07-05 시오노기세야쿠 가부시키가이샤 Ampk 활성화 작용을 갖는 복소환 유도체
PT3297992T (pt) 2015-05-22 2020-03-17 Chong Kun Dang Pharmaceutical Corp Compostos derivados de alquilo heterocíclicos como inibidores seletivos da histona desacetilase e composições farmacêuticas que compreendem os mesmos
ES2969743T3 (es) * 2015-09-10 2024-05-22 Becton Dickinson Co Análogos de la ciclofosfamida para uso como inmunógenos y conjugados en un inmunoensayo para la ciclofosfamida y la ifosfamida
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
CN106905191B (zh) * 2017-03-05 2019-03-29 北京化工大学 一种含有羟肟酸基团的氮芥类化合物及其制备方法和用途
CN106883217B (zh) * 2017-04-01 2020-05-22 清华大学深圳研究生院 一种核苷碱基异羟肟酸衍生化合物及其制备方法与应用
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) * 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) * 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
US20210085796A1 (en) * 2017-07-28 2021-03-25 Yale University Anticancer drugs and methods of making and using same
CN111107939B (zh) 2017-09-21 2022-04-12 贝克顿·迪金森公司 引导有害污染物样品的收集的系统和模板及使用其的方法
USD859683S1 (en) 2017-09-21 2019-09-10 Becton, Dickinson And Company Collection device
JP7223749B2 (ja) 2017-09-21 2023-02-16 ベクトン・ディキンソン・アンド・カンパニー 危険汚染物質の試験における高ダイナミックレンジの分析器
AU2018337030B2 (en) 2017-09-21 2025-04-10 Becton, Dickinson And Company Hazardous contaminant collection kit and rapid testing
CN108299313B (zh) * 2018-01-16 2020-10-02 长沙霍滋生物科技有限公司 一种化合物及其在药学上的应用
CN109516957A (zh) * 2018-08-03 2019-03-26 杭州梯诺医药科技有限公司 Nl-101多晶型及其制备方法
BR112021001652A2 (pt) * 2018-08-03 2021-05-04 Cellix Bio Private Limited composto e composição farmacêutica
KR102645496B1 (ko) * 2018-09-01 2024-03-07 베이징 서우바이 파마슈티컬 컴퍼니 리미티드 백금계 화합물 인산염 및 그 제조 방법
EP3897625A1 (en) 2018-12-18 2021-10-27 Mundipharma International Corporation Limited Compounds for treating lymphoma or a t-cell malignant disease
CN113383222A (zh) 2019-01-28 2021-09-10 贝克顿·迪金森公司 具有集成的拭子和测试装置的有害污染物收集装置
CN112209884B (zh) * 2019-07-12 2022-11-11 杭州梯诺医药科技有限公司 1-h苯并咪唑衍生物、制备方法及其应用
CN113307829B (zh) * 2021-05-08 2022-05-24 苏州科技大学 一种以异羟肟酸衍生物为配体的铂(ii)配合物及其制备方法和应用
WO2024231293A1 (en) 2023-05-05 2024-11-14 Euro-Celtique S.A. Combinations for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
ATE310719T1 (de) 2000-09-29 2005-12-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
CA2561617A1 (en) 2004-04-05 2005-10-20 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
GB0621160D0 (en) 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
US8987468B2 (en) * 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
USRE46144E1 (en) * 2009-01-23 2016-09-13 Purdue Pharmaceutical Products L.P. Hydroxamic acid derivatives

Also Published As

Publication number Publication date
EP2389375A2 (en) 2011-11-30
HUE025349T2 (en) 2016-02-29
CA2750413A1 (en) 2010-07-29
US8609864B2 (en) 2013-12-17
CN102186842A (zh) 2011-09-14
US20140066419A1 (en) 2014-03-06
CA2750413C (en) 2016-06-21
EP2389375B1 (en) 2015-05-20
PL2389375T3 (pl) 2015-11-30
WO2010085377A3 (en) 2011-03-31
US20110269706A1 (en) 2011-11-03
ME02254B (me) 2015-12-31
USRE46144E1 (en) 2016-09-13
WO2010085377A2 (en) 2010-07-29
US9096627B2 (en) 2015-08-04
JP2012515776A (ja) 2012-07-12
ES2544803T3 (es) 2015-09-04
RS54192B1 (sr) 2015-12-31
EP2389375A4 (en) 2012-09-19
SI2389375T1 (sl) 2015-11-30
HRP20150778T1 (hr) 2015-08-28
SMT201500196B (it) 2015-10-30
DK2389375T3 (en) 2015-08-24
CY1116602T1 (el) 2018-03-07
CN102186842B (zh) 2014-07-23
PT2389375E (pt) 2015-09-17

Similar Documents

Publication Publication Date Title
JP5576402B2 (ja) ヒドロキサム酸誘導体
CN115843272B (zh) Nek7激酶的抑制剂
US9174969B2 (en) Indoline scaffold SHP-2 inhibitors and cancer treatment method
CN100369894C (zh) 氧化氮合酶抑制剂磷酸盐
EP3377059A1 (en) Inhibitors of cxcr2
JP2017528475A (ja) Ｒａｆキナーゼ阻害剤としての化合物および組成物
CZ2001934A3 (cs) Arylsulfonanilidové močoviny
AU2018350980A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
US20250243206A1 (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
JP2022524914A (ja) アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体
KR20210062044A (ko) 퀴누클리딘-3-온 유도체와 암 치료에서 이의 용도
JP2015516462A (ja) 単環式ヘテロアリールシクロアルキルジアミン誘導体
CN117069696B (zh) 一种双靶点小分子抑制剂及其制备方法和应用
JP6985764B2 (ja) アミノピリミジン系化合物、この化合物を含む組成物およびそれらの使用
CN110283174B (zh) 一类PI3Kδ抑制剂及其用途
EP3934702B1 (en) [ 18f]-labeled benzothiazole derivative as pet radiotracer
HK1173433A (en) Hydroxamic acid derivatives
CN102702134B (zh) 噻唑烷酮衍生物及其在制备抗肺癌药物中的应用
WO2025010326A2 (en) Dimeric immuno-modulatory compounds against cereblon-based mechanisms
CA3235405A1 (en) Development of novel clofarabine analogs for cancer therapy
Mohammad Synthesis of Some N-Benzyl-6-(thio and alkyl or aryl thio) Uracil derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121226

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130409

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140703

R150 Certificate of patent or registration of utility model

Ref document number: 5576402

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250